Full Press Release Details
Tau to Participate in the H.C. Wainwright 26th Annual Global Investment Conference,
the Sidoti Small-Cap Virtual Investor Conference, the
Redburn Atlantic and Rothschild & Co 2024 Radiopharma Conference, and the Lytham Partners Fall 2024 Investor Conference
-- Alpha Tau Medical Ltd. ("Alpha Tau", or the "Company") (NASDAQ: DRTS, DRTSW), the developer of the innovative
alpha-radiation cancer therapy Alpha DaRT , today announced that CFO Raphi Levy will present a corporate overview
and update at the H.C. Wainwright 26th Annual Global Investment Conference on September 10th, 2024 and in the
Sidoti Virtual Investor Conference on September 18-19th, 2024 and will participate in the Redburn Atlantic and Rothschild
& Co 2024 Radiopharma Conference on September 26th, 2024 and the Lytham Partners Fall 2024 Investor Conference on October
| Event: | H.C. Wainwright 26 th Annual Global Investment Conference |
| Date: | September 10, 2024 |
| Time: | 12:00 - 12:30PM EST |
| Location: | New York, NY |
| Event: | Sidoti Small-Cap Virtual Investor Conference |
| Date: | September 19, 2024 |
| Time: | 11:30AM - 12:00PM EST |
| Location: | Virtual |
| Event: | Redburn Atlantic and Rothschild & Co 2024 Radiopharma Conference |
| Date: | September 26, 2024 |
| Time: | 8:30AM - 2:30PM EST |
| Location: | New York, NY |
| Event: | Lytham Partners Fall 2024 Investor Conference |
| Date: | October 1, 2024 |
| Time: | 8:00AM - 7:00PM EST |
| Location: | Virtual |
Levy will be available for 1x1 investor meetings at all conferences. Please reach out to your H.C. Wainwright, Sidoti, Rothschild &
Co, or Lytham Partners representatives to schedule.
Alpha Tau Medical Ltd.
in 2016, Alpha Tau is an Israeli oncology therapeutics company that focuses on research, development, and potential commercialization
of the Alpha DaRT for the treatment of solid tumors. The technology was initially developed by Prof. Itzhak Kelson and Prof. Yona Keisari
from Tel Aviv University.
DaRT (Diffusing Alpha-emitters Radiation Therapy) is designed to enable highly potent and conformal alpha-irradiation of solid tumors
by intratumoral delivery of radium-224 impregnated sources. When the radium decays, its short-lived daughters are released from the sources
and disperse while emitting high-energy alpha particles with the goal of destroying the tumor. Since the alpha-emitting atoms diffuse
only a short distance, Alpha DaRT aims to mainly affect the tumor, and to spare the healthy tissue around it.
Relations Contact: IR@alphatau.com